Related Experiment Video
Updated: May 6, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
New oral anticoagulants: an emergency department overview
1Pathology Queensland, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Insights
Three new oral anticoagulants (NOACs) offer effective stroke prevention in atrial fibrillation and treatment for venous thromboembolism. They demonstrate comparable efficacy to warfarin with a significant reduction in intracranial bleeding.
Area of Science:
- Pharmacology
- Clinical Medicine
- Anticoagulation Therapy
Background:
- Three novel oral anticoagulants (NOACs) are now available in Australia.
- These agents are indicated for stroke prevention in atrial fibrillation and venous thromboembolism.
- NOACs have undergone extensive evaluation in large, multicenter randomized clinical trials.
Purpose of the Study:
- To discuss the pharmacology of NOACs.
- To outline indications for NOAC use.
- To cover laboratory monitoring and bleeding management for NOACs.
Main Methods:
- Review of large, multicenter randomized clinical trials.
- Pharmacological assessment of NOAC agents.
- Analysis of efficacy and safety data compared to warfarin.
Main Results:
- NOACs show equivalent efficacy to warfarin for stroke prevention and venous thromboembolism treatment.
- Major bleeding rates are comparable to warfarin.
- A significant reduction in intracranial bleeding (approximately 50%) is observed with NOACs.
- NOACs offer a simple, fixed-dose regimen with fewer drug and dietary interactions.
Conclusions:
- NOACs represent a valuable alternative to warfarin for specific indications.
- The reduction in intracranial bleeding is a key safety advantage.
- Careful consideration of bleeding management and potential irreversible bleeding is necessary.
Abstract:
As of September 2013, three new oral anticoagulants (NOACs) are now available for clinical use on the Pharmaceutical Benefits Scheme in Australia. All three are for stroke prevention in atrial fibrillation, and one will also be available for the treatment of deep venous thrombosis and pulmonary embolism. All have been evaluated in large, multicentre randomised clinical trials. These drugs show at least equivalent efficacy to the current standard of care, the vitamin K antagonist warfarin. Major bleeding rates are overall comparable with warfarin, but there is an important reduction in intracranial bleeding of approximately 50% with all NOAC agents. The NOACs are administered in a simple, fixed dose regimen. There are a few clinically important interactions with other medications or diet. Concerns exist about the potential for irreversible bleeding in the small number of patients in which that occurs. This short report will discuss the pharmacology of these agents, the indications for use, aspects of laboratory monitoring and the management of bleeding with these agents.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Drug Delivery: Enteral Route
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management

